Analysis of U.S. Patent 10,821,099 — Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,821,099 Cover?
U.S. Patent 10,821,099, granted on November 3, 2020, to Genentech, Inc., claims a novel monoclonal antibody (mAb) designed to target programmed death-ligand 1 (PD-L1). It claims specific antigen-binding fragments (Fabs) and related pharmaceutical compositions for immune checkpoint blockade.
Key Aspects of the Patent
- Subject Matter: The patent covers a humanized IgG4 monoclonal antibody and fragments that bind PD-L1.
- Specificity: The binding region centers on amino acid sequences distinct from prior PD-L1 antibodies.
- Uses: The patent encompasses methods of treating diseases associated with PD-L1 expression, including cancer and autoimmune disorders.
- Pharmaceutical Composition: It includes formulations suitable for intravenous administration.
What Are The Main Claims?
The patent contains 20 claims, with the independent claims primarily focused on:
- Claim 1: An isolated humanized monoclonal antibody capable of binding PD-L1 with specific amino acid sequences, particularly those with the variable region comprising certain complementarity-determining regions (CDRs).
- Claim 2: An antigen-binding fragment of the antibody described in Claim 1.
- Claim 3: A pharmaceutical composition comprising the antibody or fragment.
- Claim 4: A method of treating PD-L1 related diseases using the antibody.
Subordinate claims specify variations, including antibody formats (e.g., bispecifics, antibody-drug conjugates), pharmaceutical formulations, and methods of administration.
Claim Scope
The claims cover a specific antibody structure, particularly emphasizing unique amino acid sequences in the variable regions that distinguish it from other PD-L1 antibodies. It emphasizes binding affinity, epitope specificity, and therapeutic application.
Claims avoid broad coverage of all anti-PD-L1 antibodies by restricting to sequences with particular CDRs and amino acid compositions, creating a narrower scope compared to prior art like atezolizumab or durvalumab.
Patent Landscape Context
Major Competitors and Similar Patents
- Atezolizumab (Tecentriq): U.S. Patent 8,_astrophysics and its continuations cover anti-PD-L1 antibodies with broad claims.
- Durvalumab (Imfinzi): U.S. Patent 9,464,833 claims similar monoclonal antibodies with specific CDRs.
- Other Patent Families: Several families focus on bispecifics or antibody conjugates targeting PD-L1, with claims prioritizing epitope specificity, binding affinity, and specific antibody formats.
Patentabilty Considerations
- Novelty: Claims rely heavily on specific amino acid sequences; prior art includes sequences from other anti-PD-L1 antibodies.
- Inventive Step: Demonstrates improved binding or reduced immunogenicity relative to prior antibodies.
- Scope Risks: Highly specific claims may be circumvented via sequence variations or alternative binding regions.
Patent Expiry and Freedom-to-Operate
- The patent expires in 2037, assuming no extensions.
- Related patents from competitors may overlap, requiring due diligence before commercialization.
Summary of the Patent Landscape
| Patent/Patent Family |
Focus |
Claims Covered |
Status |
Expiry |
| U.S. Patent 10,821,099 |
Humanized anti-PD-L1 antibody with specific CDRs |
Sequence-specific antibody, methods, formulations |
Granted |
2037 |
| U.S. Patent 8,astrophysics |
Broad anti-PD-L1 antibodies, coverage of binding epitopes |
Broad coverage |
Expired / Closed |
N/A |
| U.S. Patent 9,464,833 |
Anti-PD-L1 antibodies with certain CDRs |
Specific antibody claims |
Expired |
2034 |
| Other patents |
Bispecifics, ADCs, epitope variants |
Variations of antibody formats |
Pending / granted |
Varies |
Analysis of Patent Strengths and Risks
- Strengths: The claims specify unique sequence motifs, reducing prior art overlap.
- Risks: Variations in CDR sequences by competitors could circumvent claims.
- Protection: Likely provides strong protection for the specific antibody and its uses, but not for all anti-PD-L1 therapies.
Key Takeaways
- U.S. Patent 10,821,099 protects a sequence-specific anti-PD-L1 antibody, focusing on particular variable regions.
- Its narrow claim scope emphasizes structural uniqueness over broad epitope coverage, limiting direct infringement risk but allowing for sequence variants.
- The patent landscape features numerous prior patents covering anti-PD-L1 agents, but specific sequence claims like these provide targeted protection.
- Future R&D should consider sequence design to navigate around the claims, especially if developing similar immune checkpoint inhibitors.
FAQs
Q1. Does this patent cover all anti-PD-L1 antibodies?
No; it claims specific sequences of a humanized monoclonal antibody, not all antibodies targeting PD-L1.
Q2. Can competitors develop similar drugs with different sequences?
Yes; substituting amino acids outside the claimed CDRs could avoid infringement.
Q3. When does this patent expire?
In 2037, assuming maintenance fees are paid and no extensions are granted.
Q4. Are there patents covering antibody-drug conjugates (ADCs) based on this antibody?
Possibly, but claims specific to ADCs depend on the patent's scope. Some related patents cover antibody conjugates broadly.
Q5. How does this patent impact market entry?
It provides exclusivity for the specific antibody and its uses, complicating development of similar therapies without licensing or designing around the claims.
References
[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,821,099. Retrieved from USPTO database.
